Sort
10,766 grants matching “checkpoint inhibitor”
Investigating the role of EphA2 receptor tyrosine kinase in anti-tumor immunity mediated through programmed cell death ligand 2 (PD-L2) in non-small cell lung cancer (NSCLC)
$29,198Eileen Shiuan · Vanderbilt University · F30 · FY2018 · CA
Small Molecule Metabolites as Predictors and Mediators of Immune Checkpoint Inhibitor Response
$29,174Ian T. Mathews · La Jolla Institute For Immunology · F31 · FY2020 · CA
Fhit as modulator of Chk1 termination and response to DNA-damaging agents
$29,044Joshua Saldivar · Ohio State University · F31 · FY2011 · CA
RADIATION INDUCED G1 CHECKPOINT ARREST IN YEAST
$28,992University Of Chicago · R01 · FY2001 · GM
P53 MEDIATED G2/M CHECKPOINT CONTROL
$28,950Thomas Jefferson University · R01 · FY2005 · CA
Investigating the role of EphA2 receptor tyrosine kinase in anti-tumor immunity mediated through programmed cell death ligand 2 (PD-L2) in non-small cell lung cancer (NSCLC)
$28,712Eileen Shiuan · Vanderbilt University · F30 · FY2017 · CA
Molecular mechanisms of genome maintenance during DNA replication and repair
$28,710Kamakoti P. Bhat · Vanderbilt University · F99 · FY2017 · CA
Modulation of the Immune System as a Strategy to Treat EGFR Mutant Lung Adenocarcinoma
$28,692Deborah O Ayeni · Yale University · F31 · FY2017 · CA
Cancer Cell Biology and Signaling Research Program
$28,689Vivek M Rangnekar · University Of Kentucky · P30 · FY2019 · CA
Cancer Cell Biology and Signaling Research Program
$28,689Vivek M Rangnekar · University Of Kentucky · P30 · FY2021 · CA
Cancer Cell Biology and Signaling Research Program
$28,689Vivek M Rangnekar · University Of Kentucky · P30 · FY2018 · CA
Cancer Cell Biology and Signaling Research Program
$28,689Vivek M Rangnekar · University Of Kentucky · P30 · FY2020 · CA
Cancer Cell Biology and Signaling Research Program
$28,689Vivek M Rangnekar · University Of Kentucky · P30 · FY2022 · CA
IDENT AND POST-TRANSLATIONAL MODIFICATION OF MITOTIC REGULATORY PROTEINS
$28,669David L Stenoien · Battelle Pacific Northwest Laboratories · P41 · FY2011 · RR
Fhit as modulator of Chk1 termination and response to DNA-damaging agents
$28,320Joshua Saldivar · Ohio State University · F31 · FY2010 · CA
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer
$28,146Lily Yang · Emory University · R01 · FY2023 · CA
Immunomodulatory Nanoparticles in Combination with Immune Checkpoint Inhibitors for the Systemic Treatment of Immunosuppressive HPV Associated Oropharyngeal Cancer
$28,091Jared Michael Newton · Baylor College Of Medicine · F31 · FY2019 · DE
Cancer Immunology
$28,000Nina Bhardwaj · Icahn School Of Medicine At Mount Sinai · P30 · FY2025 · CA
Alleviating solid stress to overcome immunotherapy resistance in metastatic breast cancer
$27,970Hadi Tavakoli Nia · Massachusetts General Hospital · F32 · FY2018 · CA
Design and Delivery of Neoantigen-based Tumor Vaccines
$27,942Christof Chiu Smith · Univ Of North Carolina Chapel Hill · F30 · FY2021 · CA
T cell mechanisms of immunotherapy response in pancreatic ductal adenocarcinoma
$27,889Emily Davis · Johns Hopkins University · F31 · FY2022 · CA
Dissecting mechanisms of immunotherapy resistance in melanoma patients
$27,865Benjamin Izar · Dana-Farber Cancer Inst · K08 · FY2019 · CA
GEN - Project
$27,846P. Todd Stukenberg · University Of Virginia · P30 · FY2024 · CA
GEN - Project
$27,846P. Todd Stukenberg · University Of Virginia · P30 · FY2025 · CA
GEN - Project
$27,843P. Todd Stukenberg · University Of Virginia · P30 · FY2022 · CA